INDGN578.00

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹13,901 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt403.10.00.00.0
Net Debt-582.0-1,530.7-1,400.3-1,400.3
Total Debt/Equity0.280.000.000.00
Net Debt/Equity-0.41-0.59-0.45-0.45
Total Debt/EBITDA0.800.000.000.00
Net Debt/EBITDA-1.15-2.86-2.26-2.20
Interest Coverage (EBIT/Interest)8.6920.6425.5225.52
Total Debt/Total Capital %22.000.000.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.